| Gayle Barbara Harris, MD | |
|
345 N Main St, Suite 242, West Hartford, CT 06117-2515 | |
| (860) 231-1644 | |
| (860) 231-8868 |
| Full Name | Gayle Barbara Harris |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 28 Years |
| Location | 345 N Main St, West Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407860661 | NPI | - | NPPES |
| 010038378CT07 | Other | TN | ANTHEM BLUE SHIELD |
| 2V6766 | Other | HEALTHNET |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 038378 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians For Women's Health, Llc | 3274430665 | 278 |
News Archive
Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.
EKF subsidiary, Selah Genomics' newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...
Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.
The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 3 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.
EKF subsidiary, Selah Genomics' newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...
Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.
The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 3 days ago
| Entity Name | Physicians For Women's Health, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801826680 PECOS PAC ID: 3274430665 Enrollment ID: O20031215000455 |
News Archive
Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.
EKF subsidiary, Selah Genomics' newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...
Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.
The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gayle Barbara Harris, MD 345 N Main St, Suite 242, West Hartford, CT 06117-2515 Ph: (860) 231-1644 | Gayle Barbara Harris, MD 345 N Main St, Suite 242, West Hartford, CT 06117-2515 Ph: (860) 231-1644 |
News Archive
Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.
EKF subsidiary, Selah Genomics' newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...
Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.
The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 3 days ago
Emily Jo Mills, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 345 N Main St Ste 201, West Hartford, CT 06117 Phone: 860-561-7222 Fax: 860-561-7228 | |
Vinay R Ranade, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 345 North Main Street, Ste 201, West Hartford, CT 06117 Phone: 860-561-7222 Fax: 860-561-7228 | |
Marian Kellner, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 345 N Main St, Suite 201, West Hartford, CT 06117 Phone: 860-231-2476 Fax: 860-231-2480 | |
Deborah S Hoffman, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 345 North Main Street, Suite 201, West Hartford, CT 06117 Phone: 860-561-7222 Fax: 860-561-7228 | |
Dr. Michael P Hemphill, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 345 N Main St Ste 201, West Hartford, CT 06117 Phone: 860-561-7222 Fax: 860-231-2480 | |
Dr. Eva Marie Carignan, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 345 N Main St, Suite 201, West Hartford, CT 06117 Phone: 860-561-7222 Fax: 860-561-7228 | |
Mrs. Abigail Elizabeth Gurall, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 345 N Main St Ste 242, West Hartford, CT 06117 Phone: 860-924-7979 |